The Conflicting Lessons Of Aduhelm

 
• By Michael McCaughan

US FDA is understandably feeling vindicated about the decision to use beta amyloid as a surrogate marker in Alzheimer’s. But the agency needs to be careful because critics of its landmark accelerated approval decision for Aduhelm are not arguing about the science.

US FDA's approval of Aduhelm has produced no shortage of drama. • Source: Shutterstock

When it comes to the role of beta amyloid as a surrogate marker for disease progression in Alzheimer’s, it is very understandable if US Food & Drug Administration officials are tempted to say, “I told you so.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards